Study on Claudin18.2 CAR-T Therapy for Patients with Advanced Gastric, Pancreatic, or Other Digestive Cancers

Program Overview

This study is exploring a new treatment called Claudin18.2 CAR-T cell therapy for patients with advanced gastric, pancreatic, or other specified digestive system cancers. The treatment involves using a patient's own immune cells, which are modified in the lab to target cancer cells with the Claudin18.2 protein. The main goals are to assess the safety of this treatment and to see if it can help shrink tumors in adults aged 18 to 75 who have these types of cancers. Participants will undergo several procedures, including blood collection, cell modification, and infusion of the modified cells, followed by long-term monitoring to ensure safety.

Description

This clinical trial is designed to test the safety and effectiveness of a new treatment called Claudin18.2 CAR-T cell therapy in patients with advanced gastric, pancreatic, or other digestive system cancers. The study involves several steps:

1. Screening and Consent: Patients will first provide consent to participate and have their tumor tissue tested for the presence of the Claudin18.2 protein.

2. Cell Collection: Eligible patients will undergo a procedure called leukapheresis to collect their immune cells, which will be modified in the lab to target cancer cells.

3. Cell Modification and Infusion: The collected cells are genetically modified to become Claudin18.2 CAR-T cells. After a preparation phase, these modified cells are infused back into the patient.

4. Follow-Up: Patients will be monitored for safety and effectiveness of the treatment, with regular check-ups and tests to track their health and response to the therapy.

The study aims to determine if this new approach can safely and effectively treat cancers that express the Claudin18.2 protein, offering a potential new option for patients with limited treatment choices.

Eligibility Criteria

Locations